Ice Control during Cryopreservation of Heart Valves and Maintenance of Post-Warming Cell Viability

Cells. 2022 Jun 7;11(12):1856. doi: 10.3390/cells11121856.

Abstract

Heart valve cryopreservation was employed as a model for the development of complex tissue preservation methods based upon vitrification and nanowarming. Porcine heart valves were loaded with cryoprotectant formulations step wise and vitrified in 1−30 mL cryoprotectant formulations ± Fe nanoparticles ± 0.6 M disaccharides, cooled to −100 °C, and stored at −135 °C. Nanowarming was performed in a single ~100 s step by inductive heating within a magnetic field. Controls consisted of fresh and convection-warmed vitrified heart valves without nanoparticles. After washing, cell viability was assessed by metabolic assay. The nanowarmed leaflets were well preserved, with a viability similar to untreated fresh leaflets over several days post warming. The convection-warmed leaflet viability was not significantly different than that of the nanowarmed leaflets immediately after rewarming; however, a significantly higher nanowarmed leaflet viability (p < 0.05) was observed over time in vitro. In contrast, the associated artery and fibrous cardiac muscle were at best 75% viable, and viability decreased over time in vitro. Supplementation of lower concentration cryoprotectant formulations with disaccharides promoted viability. Thicker tissues benefited from longer-duration cryoprotectant loading steps. The best outcomes included a post-warming incubation step with α-tocopherol and an apoptosis inhibitor, Q-VD-OPH. This work demonstrates progress in the control of ice formation and cytotoxicity hurdles for the preservation of complex tissues.

Keywords: complex tissue preservation; cryopreservation; heart valve; nanowarming; vitrification.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Cell Survival
  • Cryopreservation* / methods
  • Cryoprotective Agents / pharmacology
  • Disaccharides
  • Heart Valves
  • Ice*
  • Swine

Substances

  • Cryoprotective Agents
  • Disaccharides
  • Ice

Grants and funding

This work was funded by the U.S. Army Medical Research and Materiel Command (contract no. W81XWH-16-C-0074). The views, opinions, and findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy, or decision unless so designated by other documentation. The commercial uses of the protocols disclosed in this work are subject to a U.S. patent [] and a pending U.S. patent [].